Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia (Unbekannt)
- Neue Suche nach: Khoo, Terence
- Neue Suche nach: Gao, Lan
- Neue Suche nach: Khoo, Terence
- Neue Suche nach: Gao, Lan
In:
Expert Review of Pharmacoeconomics & Outcomes Research
;
21
, 3
;
415-423
;
2021
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia
-
Beteiligte:Khoo, Terence ( Autor:in ) / Gao, Lan ( Autor:in )
-
Erschienen in:Expert Review of Pharmacoeconomics & Outcomes Research ; 21, 3 ; 415-423
-
Verlag:
- Neue Suche nach: Taylor & Francis
-
Erscheinungsdatum:04.05.2021
-
Format / Umfang:9 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Unbekannt
-
Schlagwörter:
-
Datenquelle:
Inhaltsverzeichnis – Band 21, Ausgabe 3
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 321
-
Can we achieve affordable cancer medicine prices? Developing a pathway for changeVogler, Sabine et al. | 2021
- 327
-
How do biosimilars sustain value, affordability, and access to oncology care?Simoens, Steven et al. | 2021
- 331
-
Not cost-effective at zero price: valuing and paying for combination therapies in cancerLatimer, Nicholas R / Towse, Adrian / Henshall, Chris et al. | 2021
- 335
-
Assessing the pricing and benefits of oncology products: an updatePetrou, Panagiotis et al. | 2021
- 343
-
Early technology assessment of using whole genome sequencing in personalized oncologySimons, Martijn / Van De Ven, Michiel / Coupé, Veerle / Joore, Manuela / IJzerman, Maarten / Koffijberg, Erik / Frederix, Geert / Uyl - De Groot, Carin / Cuppen, Edwin / Van Harten, Wim et al. | 2021
- 353
-
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviewsDiaby, Vakaramoko / Almutairi, Reem D. / Babcock, Aram / Moussa, Richard K. / Ali, Askal et al. | 2021
- 365
-
Economic analyses of immune-checkpoint inhibitors to treat lung cancerVergnenegre, Alain / Chouaid, Christos et al. | 2021
- 373
-
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatmentsRui, Mingjun / Wang, Yingcheng / Fei, Zhengyang / Zhang, Xueke / Shang, Ye / Li, Hongchao et al. | 2021
- 381
-
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic reviewYu, Anthony / Huang, Eva / Abe, Momoka / An, Kang / Park, Sun-Kyeong / Park, Chanhyun et al. | 2021
- 395
-
Association of congestive heart failure with hospital outcomes among renal cancer patients in the United States: analysis of nationwide inpatient samplePark, Sun-Kyeong / Park, Lindsay / Silverman, Ciara / Heo, Ji-Haeng / Park, Chanhyun et al. | 2021
- 413
-
Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencingPasmans, Clémence T. B. / Tops, Bastiaan B. J. / Steeghs, Elisabeth M. P. / Coupé, Veerle M. H. / Grünberg, Katrien / de Jong, Eiko K / Schuuring, Ed M. D. / Willems, Stefan M. / Ligtenberg, Marjolijn J. l. / Retèl, Valesca P. et al. | 2021
- 415
-
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in AustraliaKhoo, Terence / Gao, Lan et al. | 2021
- 425
-
Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018)Darbà, Josep / Marsà, Alicia et al. | 2021
- 433
-
Patient associations and clinical oncology research: how much does a patient’s voice really matter?Franchina, Veronica / Cagnazzo, Celeste / Di Costanzo, Alessandro / Arizio, Francesca / Frazzetto, Angela Maria Elena / Gori, Stefania / Cenna, Rosita / Nicolis, Fabrizio / Procopio, Giuseppe / Adamo, Vincenzo et al. | 2021
- 441
-
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancerCheng, Li-Jen / Wong, Grace / Chay, Wen-Yee / Ngeow, Joanne / Tan, Yongqiang / Soon, Swee Sung / Aziz, Mohamed Ismail Abdul / Pearce, Fiona / Ng, Kwong et al. | 2021
- 449
-
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in SingaporeCheng, Li-Jen / Loke, Lydia / Lim, Elaine Hsuen / Pearce, Fiona / Aziz, Mohamed Ismail Abdul / Ng, Kwong et al. | 2021
- 476
-
The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998–2017Lichtenberg, Frank R. et al. | 2021
- 479
-
Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three yearsKim, Sungju / Kim, Jinhong / Cho, Hyunyoung / Lee, Kyungmin / Ryu, Chiyoung / Lee, Jong Hyuk et al. | 2021
- 489
-
Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neckLeung, Henry WC / Lang, Hui-Chu / Wang, Shyh-Yau / Leung, John Hang / Chan, Agnes LF et al. | 2021
- 497
-
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancerJiao, Boshen / Garrison, Louis P., Jr. et al. | 2021
- 503
-
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematologyAltini, Mattia / Gentili, Nicola / Balzi, William / Musuraca, Gerado / Maltoni, Roberta / Masini, Carla / Galardi, Francesca / Bertoni, Lucia / Massa, Ilaria et al. | 2021
- 511
-
Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patientsElsamany, Shereef / Elsisi, Gihan Hamdy / Hassanin, Fayza / Jafal, Mohamed et al. | 2021